Skip to main content
. 2023 Oct 14;16(10):1461. doi: 10.3390/ph16101461

Figure 2.

Figure 2

Bispecific antibodies and their target sites in lung cancer therapeutics. Bispecific antibody targets include sites in the tumor cell or an interaction with tumor cell and T-cell. Amivantamab is the only FDA-approved therapy, and other bispecific antibodies are in various stages of clinical trials.